Excess Mortality Associated With Diuretic Therapy in Diabetes Mellitus

Archives of Internal Medicine

Volumn 151, Issue 7, 1991, Pages 1350-1356

  Warram, James H ^a,b   Laffel, Lori M B ^a   Valsania, Paola ^c   Christlieb, A Richard ^a   Krolewski, Andrzej S ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; DIABETES MELLITUS; DIURETIC THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; MONITORING, PHYSIOLOGIC; PROTEINURIA; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0025770316     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400070114014     Document Type: Article

References (43)

1. 1. The Working Group on Hypertension in Diabetes. Statement on hypertension in diabetes mellitus: final report. Arch Intern Med. 1987;147:830-842.
2. 2. Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1967;213:1143-1151.
3. 3. Multiple Risk Factor Intervention Trial Research Group. Baseline resting electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-5.
4. 4. Helgeland A. Treatment of mild hypertension: a five-year controlled drug trial. Am J Med. 1980;69:725-732.
5. 5. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1:1349-1354.
6. 6. Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal result. Br Med J. 1985;291:97-104.
7. 7. Australian National Blood Pressure Management Committee. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261-1267.
8. 8. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I: reduction in mortality of persons with high blood pressure including mild hypertension. JAMA. 1979;242:2562-2571.
9. 9. Wilhelmsen L, Goran B, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertension. 1987;5:561-572.
10. 10. Smith WM, US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40(suppl 1):I98-I105.
11. 11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiologic context. Lancet. 1990;335:827-838.
12. 12. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035-2038.
13. 13. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia. 1985;28:590-596.
14. 14. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
15. 15. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750-755.
16. 16. Jarrett RJ. Cardiovascular disease and hypertension in diabetes mellitus. Diabetes Metab Rev. 1989;5:547-558.
17. 17. Klein R, Moss SE, Klein BEK, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med. 1989;149:266-272.
18. 18. Diabetic Retinopathy Study: report number 6: design, methods, and baseline results. Invest Ophthalmol Vis Sci. 1981;21:3-188.
19. 19. Diabetic Retinopathy Study: Manual of Operations. Bethesda, Md: Diabetic Retinopathy Study Coordinating Center, Office of Scientific Reporting, National Eye Institute; 1978.
20. 20. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
21. 21. Derby L, Warram JH, Laffel LMB, Krolewski AS. Elevated blood pressure predicts the development of persistent proteinuria in the presence of poor glycemic control in patients with type I diabetes. Diabete Metab. 1989;15:320-326.
22. 22. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co; 1986.
23. 23. Gross TP, Wise RP, Knapp DE. Antihypertensive drug use: trends in the United States from 1973 to 1985. Hypertension. 1989;13:I113-I118.
24. 24. Korcok M. Do antihypertensive drugs increase coronary risk? JAMA. 1981;246:2008-2009.
25. 25. Kaplan N. How bad are diuretic-induced hypokalmeia and hypercholesterolemia? Arch Intern Med. 1989;149:2649.
26. 26. Multiple Risk Factor Intervention Trial Research Group. Relationship among baseline resting ECG abnormalities, antihypertensive treatment and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-15.
27. 27. Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation. 1986;73:114-123.
28. 28. Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings in the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986;29:29-54.
29. 29. Browner WS, Hulley SB. Effect of risk status on treatment criteria: implications of hypertension trials. Hypertension. 1989;13(suppl I):I51-I56.
30. 30. Rosenman RH. Results of the Multicenter Antihypertensive Treatment Trials: therapeutic implications and the role of the sympathetic nervous system. Am J Hypertension. 1989;2:313S-338S.
31. 31. Freis E. Critique of the clinical importance of diuretic induced hypokalemia and elevated cholesterol level. Arch Intern Med. 1989;149:2640-2648.
32. 32. Walker WG, Hermann J, Murphy R, Patz A. Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc. 1985;97:94-104.
33. 33. Walker WG, Hermann J, Yin D, Murphy RP, Patz A. Diuretics accelerate diabetic nephropathy in hypertensive insulin dependent and non-insulin dependent subjects. Trans Assoc Am Phys. 1987;C305-C315.
34. 34. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
35. 35. Freis ED, Materson BJ, Flamenbaum W. Comparison of propranolol or hydrochlorothiazide alone for the treatment of hypertension, III: evaluation of the renin-angiotensin system. Am J Med. 1983;74:1029-1041.
36. 36. Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension. 1988;12:244-250.
37. 37. Urata H, Healy B, Stewart RW, et al. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab. 1989;69:54-66.
38. 38. Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med. 1988;84(suppl 3A):55-60.
39. 39. Schmieder RE, Messerli FH, Garavaglia GE, Nunez B, MacPhee AA, Re RN. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med. 1988;84(suppl 3A):136-139.
40. 40. Unger T, Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol. 1990;65:31-101.
41. 41. Cruickshank JM. Coronary flow reserve and the J-curve relation between diastolic blood pressure and myocardial infarction. Br Med J. 1988;297:1227-1230.
42. 42. Cooper SP, Hardy RJ, Labarthe DR. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-up Program. Am J Epidemiol. 1988;127:387-403.
43. 43. Alderman MH, Ooi WL, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA. 1989;262:920-924.